On Feb. 22, 2021, Adamis Pharma announced that the FDA had completed the safety review of the Companyﾒs Investigational New Drug (ﾓINDﾔ) application and has concluded that Adamis may proceed with the proposed clinical investigation of Tempol for the treatment of COVID-19.

Tempol demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity. Both inflammatory cytokines and reactive oxygen species (ROS) from cells of the immune system called macrophages and neutrophils damage the lung in Acute Respiratory Distress Syndrome (ARDS).